tracken
PureTech Health Plc - ADR Aktie News
Neutral
Business Wire
●
5 Tage alt
BOSTON--(BUSINESS WIRE)--PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with IPF.
Neutral
Business Wire
●
28 Tage alt
BOSTON--(BUSINESS WIRE)--PureTech Presents New Data from Deupirfenidone Phase 2b Open-Label Extension, Further Supporting Potential to Serve as New Standard of Care in IPF.
Neutral
Seeking Alpha
●
etwa 2 Monate alt
PureTech Health plc (NASDAQ:PRTC ) Q2 2025 Earnings Call August 28, 2025 9:00 AM ET Company Participants Allison Mead Talbot - Senior VP of Communications & Head of Investor Relations Eric Elenko - Co-Founder & President Luba Greenwood - Corporate Participant Robert Lyne - Interim Chief Executive Officer Sven Dethlefs - Corporate Participant Conference Call Participants Heidi Danielle Jacobson ...
Neutral
Business Wire
●
etwa 2 Monate alt
BOSTON--(BUSINESS WIRE)--PureTech today announces its half-yearly results for the six months ended June 30, 2025.
Neutral
Business Wire
●
2 Monate alt
BOSTON--(BUSINESS WIRE)--PureTech Demonstrates Strategic and Scientific Leadership in Idiopathic Pulmonary Fibrosis at 2025 IPF Summit.
Neutral
Business Wire
●
2 Monate alt
BOSTON--(BUSINESS WIRE)--PureTech Health: Notice of Half-Yearly Results.
Neutral
Business Wire
●
2 Monate alt
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint.
Neutral
Business Wire
●
3 Monate alt
BOSTON--(BUSINESS WIRE)--PureTech Announces the Launch of Celea Therapeutics with a Mission to Transform the Treatment of Respiratory Diseases.
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
